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SUMMARY  
Background: Although a direct causal relationship 
between hyperuricaemia and stroke continues to be 
debated, strong associations between serum uric acid 
(SUA) and cerebrovascular disease exist. Very few 
studies have been conducted to evaluate the frequency 
and association between this potentially modifiable 
biomarker of vascular risk and stroke in sub-Saharan 
Africa. Therefore the aim of this study was to examine 
the association between hyperuricaemia and the tradi-
tional risk factors and the outcomes of stroke in Ghana-
ian patients. 
Methods: In this prospective observational study, 147 
patients presenting with stroke at a tertiary referral cen-
tre in Ghana were consecutively recruited. Patients 
were screened for vascular risk factors and SUA con-
centrations measured after an overnight fast. Associa-
tions between hyperuricaemia and stroke outcomes 
were analysed using Kaplan-Meier and Cox propor-
tional hazards regression analysis.  
Results: The frequency of hyperuricaemia among 
Ghanaian stroke patients was 46.3%. Non-significant 
associations were observed between hyperuricaemia 
and the traditional risk factors of stroke. SUA concen-
tration was positively correlated with stroke severity 
and associated with early mortality after an acute 
stroke with unadjusted hazards ratio of 2.3 (1.4 - 4.2, 
p=0.001). A potent and independent dose-response 
association between increasing SUA concentration and 
hazard of mortality was found on Cox proportional 
hazards regression, aHR (95% CI) of 1.65 (1.14-2.39), 
p=0.009 for each 100µmol/l increase in SUA. 
Conclusions: Hyperuricaemia is highly frequent and 
associated with adverse functional outcomes among 
Ghanaian stroke patients. Further studies are warranted 
to determine whether reducing SUA levels after a 
stroke would be beneficial within our setting. 
 




Hyperuricaemia is an emerging risk factor associated 
with increased cardiovascular and cerebrovascular dis-
eases (CVD).1 This is rather paradoxical because in-
vivo and in-vitro studies have demonstrated uric acid to 
be a powerful free radical scavenger and its antioxidant 
properties would be expected to provide a number of 
benefits within the cardiovascular system.2 In contrast 
however, hyperuricaemia is linked with multiple pro-
atherogenic processes, including increased oxidative 
stress3,4, vascular smooth muscle cell proliferation5, 
and leukocyte activation.6  
 
There is also evidence suggesting strong associations 
between hyperuricaemia and obesity7, hypertension8, 
reduced HDL cholesterol9, hypertriglyceridaemia10, 
hyperinsulinaemia and reduced insulin sensitivity. 11,12 
Therefore, it is unclear whether high serum uric acid 
promotes or protects against the development of CVD, 
or simply acts as a passive marker of increased risk. 
 
In particular reference to the role of hyperuricaemia in 
stroke, it has been noted that serum uric acid is an in-
dependent predictor of stroke13,14 and two large studies 
have shown that serum uric acid independently predicts 
poor outcome in stroke patients.15,16 However, Chamor-
ro et al found that among patients with acute ischaemic 
stroke, there was a 12% increase in the odds of a good 
clinical outcome for each milligram per deciliter in-
crease of serum uric acid. Their finding indicated that 
in ischaemic stroke, the increased anti-oxidant effects 
of serum uric acid might mitigate damage.17 
 
A meta-analysis of a total of 16 studies involving 
238,449 adults revealed however that hyperuricaemia 
was associated with a significantly higher risk of both 













It was concluded that hyperuricaemia may modestly 
increase the risks of both stroke incidence and mortali-
ty and that further studies were needed to determine 
whether lowering uric acid level may have any benefi-
cial effects on stroke.18 
 
Data on the associations between hyperuricaemia and 
stroke are sorely lacking in sub-Saharan Africa where 
stroke incidence, prevalence, morbidity and mortality 
are on the ascendency.19 This study therefore sought to 
evaluate the frequency of hyperuricaemia and its asso-
ciations with the traditional risk factors of stroke as 
well as in-patient outcomes in a tertiary referral hospi-
tal in the middle belt of Ghana, West Africa. 
 
METHODS 
The Committee on Human Research Publications and 
Ethics at the Komfo Anokye Teaching Hospital 
(KATH) and Kwame Nkrumah University of Science 
and Technology approved this study. One hundred and 
forty-seven participants with case definition of stroke 
had uric acid measured on admission and were includ-
ed in this observational prospective study.  
 
Written informed consent was obtained either from 
conscious patients or their first- degree relatives when 
patients had reduced level of consciousness or aphasic. 
Patient’s socio-demographic information, history and 
clinical examination findings with emphasis on cardio-
vascular risk factors for stroke and functional outcomes 
were captured on a study questionnaire.  
 
The following definitions and techniques were used to 
identify risk factors for stroke in each subject: 
Hypertension was defined as systolic blood pressure ≥ 
140 mm Hg or diastolic pressure ≥ 90 mm Hg persist-
ing > 7 days after the acute event (World Health Or-
ganisation classification) or pre-stroke treatment with 
antihypertensive drugs.20  
 
Diabetes mellitus was defined as a previous diagnosis 
of type I or II diabetes, at least 2 random blood glucose 
readings of ≥ 11.1 mmol/l, or a fasting blood glucose 
reading of ≥ 7 mmol/l after the acute phase of stroke to 
exclude acute transient elevation of glucose as a stress 
response after stroke. 21 
 
Dyslipidaemia was defined as serum cholesterol of > 
5.2 mmol/l or high-density lipoprotein cholesterol 
(HDL-C) <40 mg/dl (1.03 mmol/l) for men and <50 
mg/dl (1.29 mmol/l) for women or pre-stroke treatment 
with a cholesterol-lowering agent.22 Hypertriglycer-
idaemia was defined as a serum triglyceride levels ≥ 
1.71mmol/l according to the AHA/NHLBI criteria.23 
 
Obesity was defined as a raised body mass index > 30 
kg/m2 in ambulant patients or waist circumference of > 
80cm in females and > 94cm in males.24  
Waist circumference was measured using a tape meas-
ure horizontally placed at the level of the superior 
crests and ensuring that the tape measure was snug and 
did not compress the skin. Measurement was made at 
the end of normal expiration.24 Current smoking status 
and alcohol intake statuses were ascertained from ei-
ther the patient or a reliable relative. Current smokers 
were defined as those who smoked at least 10 ciga-
rettes per day for 6 months or more and those who 
smoked daily for 1 year or more regardless of the num-
ber of cigarettes per day. A high alcohol intake was 
defined as ≥ 14 units per week for women, ≥ 21 units 
per week for men. 
 
Congestive heart failure was defined clinically as a 
history of dyspnoea on minimal exertion, paroxysmal 
nocturnal dyspnoea or acute pulmonary oedema or the 
presence of distended neck veins (in other than the 
supine position and in the absence of venous obstruc-
tion), bilateral ankle oedema (not caused by a condition 
other than cardiac failure), hepatomegaly, crepitations 
in the absence of pulmonary disease, positive S3, or 
chest radiographic evidence of pulmonary congestion 
(pleural fluid, pulmonary venous congestion, promi-
nent pulmonary veins) with or without cardiomegaly. 
Previous stroke was defined as history of hospitaliza-
tion for a syndrome of rapidly developing clinical signs 
of focal or global disturbance, attributed to ischaemic 
or haemorrhagic lesions in the brain with or without 
verification with computed tomography. 
 
Physical activity status of participants was to be as-
sessed using the International Physical Activity Ques-
tionnaire. However because some participants were 
either aphasic or unconscious their relatives were simp-
ly questioned on patients’ physical activity status. Re-
sponders who reported spending more than half the day 
on their feet or that they were involved with daily exer-
cise were classified as physically active. Those who 
spent less than half of the day on their feet or led a sed-
entary life were classed as physically inactive as has 
previously been applied.25 
  
Serum uric acid levels were measured using an auto-
mated analyzer Cobas Integra 400 Plus (Roche) at the 
laboratory of department of chemical pathology at 
KATH.  This laboratory is externally quality con-
trolled. Hyperuricaemia was classified as elevated if 
levels are > 420 µmol/l in men and > 360 µmol/l in 
women taking into consideration patients on thiazide 
diuretics. The National Institute of Health Stroke Scale 
(NIHSS)26 was employed to determine the severity of 
stroke within 24 hours of admission.  
 
 







Patient functional status on discharge was assessed 
using a modified Rankin Scale (mRS)27 with scores 
ranging from 0 to 6, with a score of 0 indicating no 
symptoms; a score of 5 indicating severe disability, 
confinement to bed, or incontinence; and a score of 6 
indicating death. The clinical types of stroke were de-
termined using cranial CT scans or clinically using the 
Siriraj Stroke Score28 when CT scan was not available.  
 
Statistical analyses 
The data from the questionnaire was entered into a 
Microsoft excel (2008) sheet and analysed with SPSS 
version 18. Univariate analyses of descriptive results of 
the demographic characteristics and identifiable risk 
factors were presented as percentages. The Mann-
Whitney’s U-test and the Student’s t-test were used to 
compare medians and means respectively. Bivariable 
analyses to examine the associations between hyperu-
ricaemia and the categorical variables were performed 
by constructing 2x2 contingency tables to determine 
odds ratios. Correlations between SUA concentration 
and continuous variables were also assessed by calcu-
lating either the Spearman’s coefficient or the Pear-
son’s coefficient for non-parametric and parametric 
data respectively.  
Kaplan-Meier survival curves were constructed to ex-
amine associations between hyperuricaemia and stroke 
mortality. Duration of follow up was determined by 
subtracting the date of admission from the date of ad-
mission from the date of discharge or death of patient 
from hospital. A Cox proportional hazards regression 
model was used to model the individual and simultane-
ous effects of SUA concentrations and other baseline 
variables on in-patient survival after stroke. Interac-
tions between covariates were tested by including mul-
tiplicative terms in regression models. In all cases, a 2-
tailed p-value less than 0.05 was considered significant. 
 
RESULTS 
Demographic characteristics and frequency of vascu-
lar risk factors for stroke: One hundred and forty-
seven patients with stroke were recruited with a median 
(IQR) age of 65 (52 – 72) years and a male: female 
ratio of 1.0: 1.2. The frequencies of hypertension, dia-
betes mellitus, obesity, hypercholesterolemia and phys-
ical inactivity were 87.8%, 29.3%, 58.1%, 50.4% and 





Table 1.Uric acid concentration in relation to demographic characteristics and traditional risk factors of stroke 
Risk factor Frequency 
(%) 
Mean ± SD uric acid concentration accord-
ing to risk factor status 
P value# Odds 
ratio∞ 
95% CI 
  Yes No    
Male sex 46.3 457.1 ± 230.9 455.4 ± 254.9 0.97  1.25 0.65 - 2.39 
Hypertension 87.8 457.4 ± 231.3 466.7 ± 307.7 0.88 1.85 0.65 – 5.23 
Diabetes mellitus 29.3 508.6 ± 287.8 423.9 ± 206.7 0.04 1.28 0.65 – 2.49 
Obesity 58.1 447.1 ± 217.2 475.5 ± 265.2 0.52 0.98 0.47 – 2.05 
Dyslipidaemia 50.4 469.7 ± 221.0 439.0 ± 234.3 0.47 1.0 0.48 – 2.07 
Alcohol abuse 21.8 443.8 ± 198.6 462.6 ± 251.3 0.70 0.98 0.46 – 2.08 
Physical inactivity 76.9 461.3 ± 249.9 449.3 ±210.4 0.80 0.82 0.38-1.77 
Cigarette smoking 6.1 496.8 ± 244.6 458.0 ± 240.8 0.64 1.48 0.38 – 5.76 
Cardio-embolism* 2.7 493.3 ± 280.6 450.6 ± 237.6 0.76 3.60 0.37 – 35.44 
Previous stroke 28.1 485.0 ± 193.8 446.8 ± 242.6 0.51 1.83 0.69 – 4.89 
*Cardio-embolism includes 2 cases each of Atrial fibrillation and 
congestive cardiac failure 
# p-values refer to comparison in arithmetic means of serum uric acid 
concentration between those with risk factor and those without. Val-
ues are arithmetic means ± standard deviation.  
∞ Odds ratio with 95% confidence interval, no p-values provided. 
 
The frequency of hyperuricaemia among stroke pa-
tients 
The mean ± SEM of fasting serum uric acid concentra-
tion for stroke patients was 458.5 ± 19.9 µmol/l. The 
overall frequency of hyperuricaemia among stroke pa-
tients was 46.3% (n=147). The frequency among males 
was 49.3% (n=67) and among females was 43.8% 
(n=80). The number of stroke patients with hyperu-
ricaemia increased with increasing age regardless of 
gender. Among 12 study participants on thiazide diu-
retics, 5 were hyperuricaemic while one out of twelve 
(12) patients who were on Aspirin had hyperuricaemia. 
One patient had gout and was on daily allopurinol for 
control of symptoms. 
 
Associations between hyperuricaemia and the tradi-
tional risk factors of stroke 
As shown in table 1 the serum uric acid concentration 
was significantly higher in diabetic patients than non-
diabetics with p=0.04. Additionally SUA was positive-
ly correlated with serum triglyceride concentration 
(spearman’s r=0.28, p-value of 0.003). The odds ratios 
testing associations between hyperuricaemia and the 
traditional risk factors of stroke are also shown on table 
1 which reveals no significant association between 












Association between serum uric acid concentration 
and severity and types of stroke 
There was a positive correlation between serum con-
centration of uric acid at presentation and severity of 
stroke assessed using the NIHSS, Pearson’s r=0.25, 
p=0.003. The difference in the mean ± SEM serum uric 
acid concentration in ischaemic and haemorrhagic 
stroke types of 439.4 ± 24.2 µmol/l vs 485.9 ± 24.2 
µmol/l, p=0.30 respectively was not significantly dif-
ferent.  
 
Table 2 Cox proportional hazards multiple regression 
analysis of determinants of mortality in acute stroke in 
Kumasi. 
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SUA * NIHSS   0.99 
(0.991.00) 
0.01 
SUA * NIHSS interaction terms between serum uric 
acid concentration and NIHSS on admission 
 
Association between hyperuricaemia and outcomes of 
stroke 
Fifty-eight (39.5%) out of 147 patients died on admis-
sion. Among stroke survivors (n=89), 2.2%, 4.5%, 
9.0%, 13.5%, 31.5% and 34.8% had functional out-
comes corresponding to mRS scores of 0, 1, 2, 3, 4 and 
5 respectively. As shown in figure 1, SUA concentra-
tions on admission trended positively with poor func-
tional outcomes of strokes with the mean (± SEM) se-
rum uric acid concentration among patients increasing 
progressively from 316.5 ± 64.5 to 547.8 ± 38.3µmol/l 
corresponding to modified Rankin Scale scores of 0 to 
6 respectively.  
 
The mean ± SEM serum uric acid concentration of 
stroke survivors of 400.3 ± 19.0 µmol/l was signifi-
cantly lower than that of those who died on admission 
547.8 ± 38.3 µmol/l, p-value of 0.0002. A logistic re-
gression analysis showed a strong relationship between 
hyperuricaemia and early death after stroke with an 
odds ratio of 2.91; 95% confidence interval (CI) 1.47 – 
5.78; p=0.002.  
 
This association was further confirmed on survival 
analysis shown in figure 2 where patients with elevated 
serum uric acid after a stroke had a hazard ratio of 2.33 
(95% CI 1.75 – 2.92, p= 0.001) of early mortality com-
pared with normouricaemic patients. The association 
between stroke mortality and hyperuricaemia was 
stronger in patients with ischaemic strokes in compari-
son with those with haemorrhagic strokes.  
Indeed the hazard ratio of mortality among ischaemic 
stroke patients with hyperuricaemia was 4.72 (95% CI 
1.6 - 20.2, p=0.008) while that of those with haemor-





Figure 1 Serum uric acid and functional outcomes of 
stroke. Dose-response plot of the mean (± standard 
error of mean) admission serum uric acid concentration 
and functional outcomes of stroke patients assessed 
using the modified Rankin scale.  
 














HR (95%CI) =2.3 (1.4 - 4.2)
p= 0.0014
Normouricaemia, n=   79                                    58                                    23                                     9                                      2
Hyperuricaemia, n=    68                                     46                                   14                                      5                                     1                










Figure 2 A graph showing a Kaplan - Meier survival 
plot of vital status of patients with normouricaemia 











An independent association between increasing SUA 
concentration and mortality was noted in a Cox propor-
tional hazards regression model, adjusted HR (95% CI) 
of 1.65 (1.14-2.39), p=0.009 for each 100µmol/l in-
crease in SUA.  
A significant interaction between severity of stroke and 
SUA on mortality was also observed in this model, 
shown in table 2. As shown in figure 3, at concentra-
tions below 300 µmol/l the case fatality rate was 
27.5%, gradually increasing to 28.9% between 300 – 
450µmol/l and exponentially to 45.7% and 67.0% at 
concentration ranges of 450 - 600µmol/l and above 
601µmol/l respectively.  
Figure 3 Serum uric acid and crude mortality rates of 
stroke.  
 
Figure 3 shows a graph of dose - response relationship 
between serum uric acid concentrations and crude mor-
tality rates in subjects with stroke. Crude mortality rate 
at each quartile of serum uric acid concentration was 
calculated by dividing the number of deaths by the total 
number of subjects at that quartile of serum uric acid. 
 
DISCUSSION 
The main observations in our study were as follows: 
there is a high frequency of hyperuricaemia (46.3%) 
among Ghanaian stroke patients. Secondly the associa-
tion between hyperuricaemia and the traditional risk 
factors among stroke patients was either weak or non-
significant probably because of small sample size of 
the study. Thirdly there was a correlation between SUA 
and severity of stroke and an association between 
hyperuricaemia and poor functional outcomes. Most 
significantly, a potent dose-response association be-
tween stroke mortality and SUA was observed in this 
cohort. The findings from this observational prospec-
tive study support the notion that SUA is an adverse 
prognostic marker and an indicator of the severity of 
stroke among Ghanaians. 
  
Our findings are consistent with the body of scientific 
evidence. Among a cohort of Congolese patients, hype-
ruricaemia was found to be predictor of stroke and all 
cause mortality29. Karagiannis et al. found that elevated 
SUA was strongly associated with early death among 
435 patients presenting with stroke at Thessaloniki, 
Greece16. Weir and colleagues extended these findings 
in a study involving 3731 subjects, by noting that pa-
tients with elevated SUA concentrations measured 24 
hours after the onset of stroke were more likely to have 
adverse outcomes such as death or placement in care. 
Additionally hyperuricaemia in these patients predicted 
the subsequent occurrence of vascular events such as 
ischaemic stroke, myocardial infarction, or vascular 
death 90 days after the stroke.15 We found an incre-
mental trend between SUA and adverse functional out-
comes among stroke survivors (figure 1) as well as 
stroke mortality (figures 2 and 3). 
 
Regarding the association between stroke mortality and 
hyperuricaemia, we noted that the association was 
much stronger among patients presenting with is-
chaemic strokes- HR of 4.72 (95% CI 1.6 - 20.2, 
p=0.008)- than hemorrhagic strokes -1.44 (95% CI  
0.77 – 2.98). Indeed a large prospective cohort study 
involving 41,879 men and 48,514 women aged > 35 
years conducted in Taiwan with a mean follow-up of 
8.2 years corroborated this association between hyperu-
ricaemia and adverse outcomes after ischaemic stroke 
with a hazard ratio of 1.35 (p<0.02). 30 
 
These findings together with those from this study sug-
gest that hyperuricaemia in the setting of stroke carries 
a strong risk of an adverse outcome and may be neuro-
toxic as suggested by the worse neurological functional 
outcomes (figure 1). A direct mechanistic role for 
hyperuricaemia in atherogenesis and the clinical course 
of cerebrovascular disease has been suggested by the 
links between elevated uric acid and increased produc-
tion of oxygen free radicals31, accelerated oxygenation 
of low-density lipoproteins which facilitates lipid pe-
roxidation4, impairment of nitric oxide production with 
subsequent activation of the renin-angiotensin sys-
tem32, induction of endothelial dysfunction and smooth 
muscle cell proliferation.5, 33  
 
Furthermore, uric acid has been found in rats to stimu-
late the synthesis of monocyte chemoattractant protein-
1 by vascular smooth muscle cells6, which is known to 
have a key role in stimulating macrophage infiltration 
in atherosclerotic vessels.34  
 









  total number     40                          42                          35                          27
no. alive            29                          32                         19                           9












Finally, hyperuricaemia increases platelet adhesiveness 
and aggregation.31 All these factors are important for 
the development and progression of atherosclerosis and 
may explain the especially strong association between 
uric acid and carotid atherosclerosis, a well-known risk 
factor for stroke.2, 35 
 
In spite of these compelling lines of evidence from 
epidemiological and experimental studies, a few well-
conducted human clinical studies have produced con-
tradictory findings. Chamorro et al for instance meas-
ured SUA concentrations among 881 consecutive is-
chaemic stroke patients at the onset of ischaemic symp-
toms and found an inverse correlation between SUA 
and early neurologic impairment and final infarction 
size on computed tomography or magnetic resonance 
imaging with a positive association between increasing 
SUA concentration and good clinical outcomes.17 In 
another intriguing study, Brouns et al followed the ki-
netics of SUA on admission and at 24 hours, 72 hours, 
day 7, month 1 and month 3 after a stroke in 199 pa-
tients and demonstrated that a significant decline in 
serum uric acid concentrations occurred within the first 
week after a stroke and this decrease correlated with 
more severe stroke, unfavourable stroke evolution, and 
poor long-term stroke outcome.36 These findings sup-
port an opposing school of thought that a high concen-
tration of SUA could be neuroprotective and has anti-
oxidant properties in the setting of an acute stroke.  
 
Muir et al have demonstrated in a pilot randomised 
double-blinded study that the administration of 300mg 
of the hypouricosuric agent, allopurinol for 6 weeks 
produced significant reductions in serum intercellular 
adhesion molecule (ICAM) concentrations compared 
with a lower dose of 100mg of allopurinol or a place-
bo37. Serum ICAM is a pro-inflammatory molecule 
which serves as a surrogate marker of vascular and 
metabolic health. Thus further studies are needed to 
determine whether reductions in SUA after stroke may 
have beneficial clinical effects. 
 
A limitation of this study is that only 19 out of 147 
(13%) had cranial CT scans to confirm and type strokes 
at presentation. Thus clinical types of stroke were de-
termined using the Siriraj stroke scale. 
 
CONCLUSION 
This study has identified a high frequency of hyperu-
ricaemia among Ghanaian patients presenting with 
stroke. Hyperuricaemia among stroke patients is 
strongly associated with worse functional outcomes 
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